News | July 05, 2023
Biocon Biologics expands footprint in emerging markets
Takes over the commercialization of Biosimilars Business from Viatris in 70+ countries
Takes over the commercialization of Biosimilars Business from Viatris in 70+ countries
The transaction represents an enterprise value of €275 million, an estimated 2023 EV/EBITDA multiple of 18x
The identified products for Active Pharmaceutical Ingredients (API) will be developed under the CRAMS and CDMO models
Survodutide has a novel mechanism of action (agonism of the dual GCG/GLP-1 receptors) that may have direct effects on energy expenditure in the liver in addition to decreasing appetite
Lilly to further investigate retatrutide for the treatment of obesity in the TRIUMPH phase 3 clinical program
Dr. Reddy's aims to roll out its trade generics across cities and towns in India
GenWorks has scaled up its e-commerce platform in terms of building traffic
This patent-pending, high-efficiency chromatography media is used for the purification of novel peptide-based pharmaceuticals in the GLP-1 agonist class including type 2 diabetes and obesity treatments
Urges Innovators to produce quality products that can be deployed at scale
Total investments could reach €70 million, of which approximately 15% in R&D and 85% in capex, that would be deployed from 2026
Subscribe To Our Newsletter & Stay Updated
